ASCO 2024 - Thanos Zomas

Great advances in cancer care have led to a new phase of research in certain cancers - in areas where a high rate of cure has been established, the focus is shifting to quality of life, side effects, and secondary malignancies.
Hodgkins lymphoma is a key example of this phenomenon and at ASCO 24 Editor in Chief Jonah Comstock spoke with Dr Thanos Zomas, global medical lead for lymphoma and leukemia at Takeda Oncology about new research on Adcetris, Takeda’s ADC for Hodgkins.
In a large phase 3 study, an independent research group showed that they could match and even exceed the efficacy of standard of care and reduce the toxicity by using a targeted agent.
Zomas discusses why this kind of progress is so important in diseases like Hodgkins lymphoma that mostly affect younger people with many years of life ahead of them. He talks more generally about the different approaches to refining existing therapies to improve safety including adaptive approaches based on patient response.
He also gives a high level view of antibody-drug conjugates as a trend and talks about why they are proving to be such a powerful weapon in the fight against cancer.
Check out the whole video below for more details on the new Adcetris research and a look into some of the larger trends on display in Chicago one month ago.
Subscribe to the pharmaphorum RUclips channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/